# Patent

## Title
Conjugate vaccine against group B streptococcus

## Abstract

The United States government has certain rights in the present invention pursuant to Grant No. HL-47313 from the National Institutes of Health.

## Background
Development of new antimicrobial agents and improved public health conditions have not substantially reduced the frequency of infections caused by Staphylococcus aureus. Staphylococci are the leading cause of osteomyelitis, septic arthritis, endocarditis, wound and foreign body infections. What constitutes the challenge in the treatment of staphylococcal infections is that staphylococci may resist treatment with conventional antimicrobial agents because of difficulties in achieving and maintaining therapeutically active concentrations of antibiotics in tissues which are either poorly vascularized (like bone) or harbor colonies of bacteria where diffusion is impaired (such as biofilms on surgical implants). Paradoxically, advances in the field of medical therapy have contributed to a steady increase of in the number of infections caused by coagulase-positive and -negative staphylococci by creating more situations in which these opportunistic pathogens find a suitable environment to multiply.

First described by Ogston more than a century ago, S. aureus has remained a mysterious pathogen. It is obvious that its virulence is multifactorial, and related to the production of a wide variety of extracellular and cell surface bound pathogenicity factors. The relative importance of these factors may vary depending on the site and stage of an infection, and various models have been proposed to explain the roles of individual factors. The most effective way to prevent an infection is early in the process of infection, before bacteria manage to multiply.

The concept of preventing infection by interfering with the initial microbial adherence to the host tissue is in this context particularly appealing. The molecular mechanisms of microbial adherence have been extensively studied for many Gram-negative bacteria, and only in the last decade shed some light on possible adhesion mechanisms of Gram-positive bacteria. Historically speaking, the association of S. aureus with fibrinogen (mediated by what was subsequently termed clumping factor, or less correctly, bound coagulase) described by Much in 1908 appears to be the first description of a putative adherence mechanism.

When Kuusela described binding of S. aureus cells to the then newly rediscovered fibronectin, a new chapter in the study of S. aureus adherence was opened (Kuusela, P., et al., Nature 276:718-720 (1978)). Soon, many other observations followed, indicating that 1) fibronectin may be recognized by many different bacteria, both Gram-positive and Gram-negative, and 2) in addition to fibronectin, many other connective tissue proteins are recognized and bound by bacteria. Currently the rate of description of new interactions between bacteria and connective tissue components, or eukaryotic cell surface components like integrins, seems to be limited only by the rate at which these components are discovered.

In addition to fibrinogen and fibronectin, S. aureus strains associate with several other adhesive eukaryotic proteins (many of which belong to the family of adhesive matrix proteins)--laminin (Lopes et al., Science 229:275-277 (1985)), vitronectin (Chhatwal, G. S., et al, Infect Immun. 55:1878-1883 (1987)), bone sialoprotein (Ryden, C., et al., Eur. J. Biochem. 184:331-336 (1989)), proteoglycans (Ryden et al., 1989), endothelial cell membrane protein (Tompkins, D.C., et al., J. Clin. Invest. 85:1323-1327 (1990)) and collagens. These interactions have mostly been studied in systems in which either soluble host proteins or microparticles coated with these proteins are incubated with bacteria. Indications that these bacteria-protein interactions play a role in virulence have been demonstrated in only few instances. Progress in this field has been relatively slow and may require a detailed knowledge of the bacterial components that serve as receptors for the matrix proteins.

As reported in the Apr. 15, 1994 edition of Science, for several years now, medical microbiologists have been tracking an alarming trend in microbial infection. It has been found that antibiotics that once killed bacterial pathogens with ease are becoming ineffective. This is the result of the remarkable ability of bacteria eventually to develop resistance to virtually every antibiotic medical research has utilized against them. Particularly worrisome is the relative dearth of new antibiotics on the horizon. And of the new antibiotics proposed, few employ novel modes of action that would be more difficult for bacteria to circumvent. Researchers and manufacturers have assumed that they have solved the problem of bacterial infection--after all, the market consists of over 100 antibiotics--and many pharmaceutical firms and research organizations have abandoned work on antibiotics or refused to fund these projects.

There are today strains of Staphylococcus which often cause fatal hospital infections that are immune to all but one existing antibiotic. It is predicted that it will not be long before that final barrier will fall.

An object of the present invention is to provide the nucleotide sequence of an MHC II-antigen protein analog gene from Staphylococcus aureus.

A further object of the present invention is the provision of the amino acid sequence of an MHC II-antigen protein analog from Staphylococcus aureus.

Another object of the present invention is to provide a vaccine for inhibiting staphylococcal infections.

An additional object of the present invention is to provide a method for using the MHC II-antigen protein analog from Staphylococcus aureus as an in vivo vaccine for inhibiting staphylococcal infections.

A further object of the present invention is to provide a method for using derivatives of the MHC II-antigen protein analog from Staphylococcus aureus as an in vivo vaccine for inhibiting staphylococcal infections.

An additional object of the present invention is a method for vaccine production in humans or in animals.

Thus, in accomplishing the foregoing objects, there is provided in accordance with one aspect of the present invention the nucleotide sequence for gene for the MHC II-antigen protein analog from Staphylococcus aureus, and the amino acid sequence for the MHC II-antigen protein analog from Staphylococcus aureus.

In accomplishing an additional object, there further is provided in accordance with the present invention an in vivo vaccine comprising the entire MHC II antigen protein, or fragments of the protein, alone or in combination with other S. aureus antigens, necessary for the elicitation of therapeutically active antibodies.

In a specific embodiment of the present invention, there is provided derivatives of the MHC II-antigen protein analog from Staphylococcus to be used as an in vivo vaccine comprising an intact version of the polypeptide, or biologically active subfragments, alone or in a mixture with other antigens from Gram-positive organisms.

In an additional embodiment of the present invention, there is provided a method for using the MHC II-antigen protein analog from Staphylococcus or its derivatives as an in vivo vaccine comprising the steps of expression of the MHC II antigen analog protein in a recombinant system, purification to homogeneity, and immunization using the protein in a pharmaceutically acceptable dispensing agent. Different routes of immunization may be used and various adjuvants may be added so that optimal dosage can be achieved. In order to obtain sufficient levels of antigen in the body, multiple injections will be used. Additionally, passive immunization of affected individuals is used if needed.

Other and further objects, features and advantages will be apparent and the invention more readily understood from a reading of the following specification and by reference to the accompanying drawings forming a part thereof, wherein the examples of the presently preferred embodiments of the invention are given for the purposes of disclosure.

FIG. 1 shows the gene encoding the MHC II-antigen like staphylococcal protein as well as the protein based on the deduced amino acid sequence. The gene is comprised of 2070 nucleotides and codes for a signal sequence (S) that is 30 amino acids long, a segment with a unique sequence (U), and six repeated segments of 100 amino acids each. The six segments contain a subsegment that is 30 amino acids in length and that has a high degree of similarity with various MHC class II antigens.

FIGS. 2A-2K show the entire nucleotide sequence of the gene and the deduced amino acid sequence. Nucleic acid sequence IDs numbers 1 and 2 are indicated.

FIG. 3 represents a comparison of the subsegment of the repeat units in the staphylococcal protein and various MHC II sequences. Amino acid Sequence IDs 3 through 8 are indicated.

FIG. 4 illustrates the MHC II-antigen like staphylococcal protein gene introduced into the pQE expression vector and used to express the recombinant protein.

FIG. 5A, FIG. 5B, and FIG. 5C show the binding of radiolabelled fibronectin and a radiolabelled synthetic peptide (mimicking a vitronectin (Vn) sequence) to the native protein purified as shown, as well as to recombinant version of the protein expressed in E. coli. Lane 1 shows native S. aureus LiCl purified protein, lane 2 is sonicated recombinant E. coli clone and lane 3 is sonicated E. coli without S. aureus gene.

It will be readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

As used herein, the term "extracellular matrix proteins" refers to four general families of macromolecules--collagens, structural glycoproteins, proteoglycans and elastins--that provide support and modulate cellular behavior.

The term "MHC Class II antigens" or "MHC II antigens" as used herein refers to cell-surface molecules that are responsible for rapid graft rejections and are required for antigen presentation to T-cells.

As used herein, the term "in vivo vaccine" refers to immunization of animals with proteins so as to elicit a humoral and cellular response that protects against later exposure to the pathogen.

As used herein, fie term "autoimmune diseases" refers to an abnormal response against self-antigens.

Staphylococcus aureus can bind a number of different extracellular matrix proteins. Recent studies have shown that one particular Staphylococcus protein has the capacity of binding several different matrix proteins. This staphylococcal protein has been found to occur in two different forms, a 68 kD form and a 70 kD form. The gene encoding this staphylococcal protein has been cloned and sequenced. Comparison with existing data bases (Gen Bank EMBL) show that this staphylococcal protein has a high degree of homology with eukaryotic MHC Class II antigens.

Further analyses of the binding specificities of this protein reveal that it functionally resembles an MHC II antigen in that it binds synthetic peptides. Thus, in addition to mediating bacterial adhesion to extracellular matrix proteins, one may expect this protein to play a role in staphylococcal infections by suppressing the immune system of the host. Therefore, this protein, or derivatives thereof, are useful as important vaccine components for protection against staphylococcal infections.

In one embodiment of the present invention there is a nucleotide sequence (SEQ ID NO:1) that codes for a gene that is transcribed and translated into an MHC II-antigen like staphylococcal protein. There is further provided the amino acid sequence of the MHC II-antigen like staphylococcal protein having the formula of SEQ ID NO:2.

In another embodiment of the present invention, an in vivo vaccine against staphylococcal infections is provided. This vaccine comprises an MHC II antigen protein analog which elicits a humoral and cellular response protects against later exposure to the antigen.

Moreover, a method for using the in vivo vaccine is provided. The method involves the steps of expression of the MHC II antigen analog protein in a recombinant system, purification to homogeneity, and immunization using the protein in a pharmaceutically acceptable dispensing agent. Different routes of immunization may be used and various adjuvants may be added so that optimal dosage can be achieved. In order to obtain sufficient levels of antigen in the body, multiple injections will be used. Additionally, passive immunization of affected individuals is used if needed.

The following examples are offered by way of illustration and are not intended to limit the invention in any manner.

The S. aureus clinical isolates were provided by the Department of Orthopedics, Bowman Gray School of Medicine, Winston-Salem, N.C., and the Clinical Pathology Laboratory, School of Medicine, University of Alabama at Birmingham (Homonylo-McGavin, M., et.al., Infect. Immun. 61:2479-2485 (1993)).

E-coli DH-5.alpha. (Hanahan, D., J. Mol. Biol. 166:557-580 (1983)) and M15 (Henco, K., The QIAexpressionist, DIAGEN GmbH, Dusseldorf (1991)) were used as bacterial hosts. The plasmid vectors were BluescriptSK(+) (Stratagene Cloning Systems, La Jolla, Calif.) and pQE30 (Henco, K., The QIAexpressionist, DIAGEN GmbH, Dusseldorf (1991)). Chromosomal DNA was prepared from S. aureus FDA 574 as previously described (Marmur, J., J. Mol. Biol. 3:208-218 (1961)).

E. coli clones of the strain DH-5.alpha. were grown in Luria broth (LB), supplemented with ampicillin (100 .mu.g/ml). The E. coli clone pQE20 (fusion of the pQE30 with the gene of the broad spectrum adhesin), was grown in LB supplemented with ampicillin at a concentration of 100 .mu.g/ml and kanamycin at a concentration of 25 .mu.g/ml. The clone was induced for expression of the recombinant gene with 1 mM isoprophyl .beta.-thiogalactoside (IPTG) for 4 hours.

S. aureus FDA 574 was grown in LB over night at 37.degree. C. for the subsequent purification of the broad spectrum adhesin. The S. aureus clinical isolates were grown 15 hours in either Tryptic Soy Broth or LB.

Overnight cultures of S. aureus cells were harvested by centrifugation, boiled in PBS 2% sodium dodecylsulfate (SDS) and 5% 2-mercaptoethanol for 3 minutes and loaded onto a SDS-polyacrylamide gel (PAGE) for electrophoresis. specificity

Overnight grown bacterial cultures of S. aureus FDA 574 were harvested by centrifugation (3,600.times.g, 20 min) and resuspended in 1/10 volume of 1M LiCl (pH 6.0). The cell suspension was incubated at 45.degree. C. for 2 hours with gentle agitation. Subsequently, the cells were removed by centrifugation (3,600.times.g 30 min), and the supernatant containing the solubilized protein was collected. The protein was precipitated from the LiCl extracts by addition of ammonium sulfate to a final concentration of 60% (wt/vol), followed by gentle stirring overnight at 4.degree. C. The precipitated protein was recovered by centrifugation (15000.times.g, 30 min), and the pellet was resuspended in a minimal volume of 10 mM Tris-HCl, pH 7.5.

Iodination of ligands were conducted by either the chloramine-T method of Hunter (Hunter, H. and K. M. Wier, Handbook of Experimental Immunology, p. 14.1-14.40 (1968)) or the lactoperoxidase method (Morrison, M., and G. S. Bayse, Biochemistry 9:2995-3000 (1970)) using Enzymobeads (Bio-Rad Laboratories, Hercules, Calif.).

Proteins were fractionated by SDS-PAGE using a gradient gel of 3 to 15% acrylamide or a 10% acrylamide SDS-PAGE gel and the buffer system of Laemmli (Nature 227:680-685 (1970)). The proteins were transferred to Immobilon P.TM. (Millipore, Bedford, Mass.) membranes with the Bio-Rad Trans Blot.TM. apparatus and the transfer buffer of Towbin et al. (Towbin, H., et al., PNAS 76:4350-54 (1979)). Additional protein binding sites on the membranes were blocked by incubation for 2 hours to 15 hours in phosphobuffered saline (PBS) containing 3% (wt/vol) bovine serum albumin (BSA). Membranes were then incubated overnight at 4.degree. C. with gentle agitation in a solution containing 5.times.10.sup.5 -6.times.10.sup.7 cpm of .sup.125 I-labeled ligand or in PBS containing 0.1% BSA. Subsequently, the membranes were washed extensively with PBS containing 0.1% Tween.TM., air dried, and exposed to Fuji RX-100 X-ray film for anywhere from 12 to 36 hours.

LiCl purified protein from S. aureus FDA 574 was blotted to Immobilon P.TM. and N-terminal sequenced in the Core Facility at Baylor College of Medicine, Houston, Tex. Peptide fragments derived from the broad spectrum adhesin of S. aureus strain Newman were obtained by cleaving the protein with trypsin and purified on FPLC. The N-terminal sequence of the purified peptides were sequenced according to the method in the University of Alabama at Birmingham Cancer Center Protein Analysis and Peptide Synthesis Core Facility.

Polyclonal antibodies raised in rabbits against purified S. aureus (FDA 574) broad spectrum adhesin were used to screen a lambda-gt 11 gene library (CLONTECH Laboratories, Inc., Palo Alto, Calif.) of the S. aureus FDA 574 strain. One clone with a 5.7 kb insert was detected and was subsequently used as a template for Polymerase Chain Reaction (PCR) analysis using a primer pair with sequences derived from the S. aureus 25923 OMP-70 sequence (SwissProt Database #P21223). This OMP-70 sequence was not the complete sequence and contained only the four hundred first nucleotides of a gene coding for a putative 70 kD outer surface protein, however, this sequence coded for nearly the same amino acids obtained from peptide sequences derived from the broad spectrum adhesin implicating that the two proteins were very closely related. A 400 nucleotide fragment obtained from the PCR reaction was cloned into Bluescript. DNA was sequenced using the Sanger method (Sanger, F. et.al., PNAS 74:5463-5467 (1978)) with the Sequenase.TM. DNA sequencing kit (U.S. Biochemical, Cleveland, Ohio) and the thermocycling sequencing method using Circum Vent Thermal Cycle Dideoxy DNA Sequencing Kit (New England BioLabs, Beverly, Mass.). The sequence coding for the 10 amino acids after the putative signal sequence corresponded exactly to the amino acid sequence obtained from the N-terminal sequence of the LiCl purified protein of S. aureus FDA 574.

Additional lambda-gt 11 clones were isolated by using a random prime labeled gene fragment from the cloned 400 bp fragment as a probe in a plaque hybridization assay. The plaques were detected with the ECL system by Amersham. DNA from the lambda plaques were cloned into the Bluescript vector and sequenced with the above mentioned DNA sequencing methods. Various oligonucleotides corresponding to sequences from the Bluescript clones were used as DNA sequencing primers.

The construction of the recombinant plasmid pQE20, containing the gene for the broad spectrum adhesin fused to the 6 histidine residues tag of pQE30, was obtained by inserting a 2 kb DNA fragment amplified from chromosomal S. aureus FDA 574 DNA into the cleavage sites Bam HI/Sal I of plasmid pQE 30. The primers ZPCR6 5'CGGGATCCGCAGCTAAGCAAATAGATA (SEQ ID NO:24) 3' and ZPCR9 5'GCGTCGACGCGGCAAATCACTTCAAGT (SEQ ID NO:25) were used in the PCR reaction. The primers contain the restriction cleavage sites Bam HI and Sal I respectively (underlined). aureus as a virulence factor

In order to evaluate the importance of the broad spectrum adhesin as a virulence factor in staphylococcal-induced diseases such as septic arthritis osteomyelitis and endocarditis, isogenic mutants are constructed and compared with its parent strains in animals models. Histopathological as well as bacteriological analysis is performed.

In the first class of mutants, the gene for the broad spectrum adhesin is inactivated in clinical isolates. Then the mutant as well as the parent strain is tested in an animal model for the disease. In the second type of mutant, the intact gene is introduced into an S. aureus strain that lacks the gene and this transformed strain is compared to its parent strain in the appropriate animal model.

Methods: For the first class of mutations, allele replacement shuttle vectors, containing a temperature sensitive origin of replication, is constructed and introduced in E. coli. In these constructions, the gene for the broad spectrum adhesin is insertionally inactivated by a resistant marker. The shuttle vector is then introduced into the S. aureus strain of interest where the insertionally inactivated gene can recombine into the S. aureus chromosome after raising the temperature of the growth medium. A detailed description of this methodology is described in Patti, J., et al., Infection and Immunity, 62:152-61 (1994). from Staphylococcus aureus as a potential vaccine

The animal models in Example 8 are used for the evaluation of inactivated (deleted) versions of the MHC II analog. The intact MHC II analog as well as various deletions of MHC II and its peptides are used in vaccination trials in the animal models.

Methods: Different parts of the gene are expressed and the gene products are tested for their binding capacity to the different extracellular matrix proteins. Synthetic peptides mimicking the 30 amino acid subsegments of the MHC II molecules are also used. For example, the minimal stretch of amino acids in the broad spectrum adhesin for binding to the various extracellular proteins is characterized, and the binding capacity of the synthetic peptides are compared to it. Further, modifications of the synthetic peptides are made by conventional means and tested for higher binding capacity. All these different constructions are then used to immunize animals, and the antibodies are tested for inhibitory capacity of the binding of S. aureus to various extracellular matrix proteins. The animals are then challenged with the clinical S. aureus isolates and evaluated for the incidence of infection by histopathological examination and bacteriological analysis of the tissues.

The MHC II analog is tested in microtiter well assays with macrophages and CD4 T-helper cells. The peptide presenting macrophages/monocytes with their MHC II molecules are "fed" with peptide and mixed with T-helper cells as well as analog. The proliferation of the CD4 T-helper cells is stopped when the analog interferes with the peptide presentation. Macropages fed with the Vn peptide activates the T-helper cells. A determination of whether the analog can interfere in this cell assay system is made. Cell assays of this type are easily visualized under a microscope. Studies of the secretion of cytokines from the T-cells are also conducted using the cell assay. The assay is useful in this context because T-cells produce cytokines when they are stimulated. Secretion levels can be measured by using antibodies directed against the cytokines in microtiter well assays.

All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is will adapted to carry out the objects and attain the ends and advantages mentioned as well as those inherent therein. The sequences, methods, procedures and techniques described herein are presently representative of the preferred embodiments and are intended to be exemplary and ar not intended as limitations of the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention or defined by the scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 25 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2433 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: AAAAAATAGAGAAAGTCTGGCTATAATTAAGTTGCAATCACGAATTATCATAAAAAAGGA60 GTGATAATTTATGAAATTTAAGTCATTGATTACAACAACATTAGCATTAGGCGTTATAGC120 ATCAACAGGAGCAAACTTAGATACTAACGAAGCATCTGCCGCAGCTAAGCAAATAGATAA180 ATCATCAAGTTCATTACACCATGGATATTCTAAAATACAGATTCCATATACAATCACTGT240 GAATGGTACAAGCCAAAACATTTTATCAAGCTTAACATTTAATAAGAATCAACAAATTAG300 TTATAAAGATATAGAGAATAAAGTTAAATCAGTTTTATACTTTAATAGAGGTATTAGTGA360 TATCGATTTAAGACTTTCTAAGCAAGCAAAATACACGGTTCATTTTAAGAATGGAACAAA420 AAGAGTTGTCGATTTGAAAGCAGGCATTCACACAGCTGACTTAATCAATACAAGTGACAT480 TAAAGCAATTAGTGTTAACGTAGATACTAAAAAGCAAGTGAAAGATAAAGAGGCAAAAGC540 AAATGTTCAAGTGCCGTATACAATCACTGTGAATGGTACAAGCCAAAACATTTTATCAAA600 CTTAACATTTAAAAAGAATCAGCAAATTAGTTATAAAGATTTAGAGAATAATGTAAAATC660 AGTTTTAAAATCAAACAGAGGTATAACTGATGTAGATTTAAGACTTTCAAAACAAGCGAA720 ATTTACAGTTAATTTTAAAAATGGCACGAAAAAAGTTATCGATTTGAAAGCAGGCATTTA780 TACAGCGAACTTAATCAATACAGGCGGTATTAAAAATATCAATATAAATGTAGAAACTAA840 AAAGCAAGCGAAAGATAAAGAAGCAAAAGTAAATAATCAAGTGCCATATTCAATTAATTT900 AAATGGTACAACAACTAATATTCAATCTAATTTAGCATTTTCAAATAAACCTTGGACAAA960 TTACAAAAATTTAACAACAAAGGTAAAATCAGTATTGAAATCTGACAGAGGCGTTAGTGA1020 ACGTGATTTGAAACACGCAAAGAAAGCGTATTACACTGTTTACTTTAAAAATGGTGGTAA1080 AAGAGTGATACATTTAAACTCGAATATTTATACAGCTAACTTAGTTCATGCGAAAGATGT1140 TAAGAGAATTGAAGTTACTGTAAAAACAGTTTCGAAAGTAAAAGCGGAGCGTTATGTACC1200 ATATACAATTGCAGTAAATGGAGCATCAAATCCAACTTTATCAGATTTAAAATTTACAGG1260 TGACTCACGTGTAAGCTACAGTGATATCAAGAAAAAAGTTAAATCAGTATTGAAACATGA1320 TAGAGGTATCGGTGAACGTGAATTAAAATATGCCGAAAAAGCAACTTATACAGTACATTT1380 TAAAAATGGAACAAAAAAAGTGATTAATTTAAACTCTAATATTAGTCAACTGAATCTGCT1440 TTATGTCAAAGATATTAAAAATATAGATATCGATGTTAAAACTGGGGCAAAAGCGAAAGT1500 CTATAGCTATGTACCATACACAATCGCAGTAAATGGGACAACAACACCTATTGCATCAAA1560 ACTAAAACTTTCGAATAAACAATTAATTGGTTATCAAGATTTAAATAAAAAAGTTAAATC1620 AGTTTTAAAACATGATAGAGGTATCAATGATATTGAATTGAAATTTGCGAAACAAGCAAA1680 GTATACTATACACTTTAAAAATGGAAAGACACAAGTCGTTGACCTTAAATCAGATATCTT1740 TACAAGAAATTTATTCAGTGTCAAAGATATTAAAAAGATTGATATTAATGTGAAACAACA1800 ATCTAAATCTAATAAAGCGCTTAATAAAGTGACTAACAAAGCGACTAAAGTGAAGTTTCC1860 AGTAACGATAAATGGATTTTCAAATTTAGTTTCAAATGAATTTGCGTTTTTACATCCACA1920 TAAAATAACAACAAACGACTTGAATGCTAAACTTAGACTAGCGTTACGAAGCGATCAAGG1980 TATTACTAAACATGATATTGGACTTTCTGAACGCACTGTGTATAAAGTGTATTTTAAAGA2040 CGGATCATCAAAATTAGAAGACTTAAAAGCTGCGAAACAAGATTCAAAAGTATTTAAAGC2100 AACTGACATTAAAAAAGTAGACATTGAAATTAAATTTTAATCTTTAATTTTATATTAAGG2160 CATCTCACAATAGTGGGGTGCCTTTTACATTTGTAGAGATGTGATACTTGAAGTGATTTG2220 CCGCACGTTTGATAAATTTATCTAAGGCATATCAAGTTATGTTAGGAGAGATGTATAAAA2280 CTAATTAGGTATAGCGATTGACAAGTTGCTGAATAAAATATATCTTTTGATGCTTTGAAA2340 GAAGGAATAATTTTAAAAATAAAAAACCAATAATCCGAGTCATACTCATCAGATTATTGG2400 TTGAAATTAATTATCTTAAGTCATCAATTCTTT2433 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 689 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: MetLysPheLysSerLeuIleThrThrThrLeuAlaLeuGlyValIle 151015 AlaSerThrGlyAlaAsnLeuAspThrAsnGluAlaSerAlaAlaAla 202530 LysGlnIleAspLysSerSerSerSerLeuHisHisGlyTyrSerLys 354045 IleGlnIleProTyrThrIleThrValAsnGlyThrSerGlnAsnIle 505560 LeuSerSerLeuThrPheAsnLysAsnGlnGlnIleSerTyrLysAsp 65707580 IleGluAsnLysValLysSerValLeuTyrPheAsnArgGlyIleSer 859095 AspIleAspLeuArgLeuSerLysGlnAlaLysTyrThrValHisPhe 100105110 LysAsnGlyThrLysArgValValAspLeuLysAlaGlyIleHisThr 115120125 AlaAspLeuIleAsnThrSerAspIleLysAlaIleSerValAsnVal 130135140 AspThrLysLysGlnValLysAspLysGluAlaLysAlaAsnValGln 145150155160 ValProTyrThrIleThrValAsnGlyThrSerGlnAsnIleLeuSer 165170175 AsnLeuThrPheLysLysAsnGlnGlnIleSerTyrLysAspLeuGlu 180185190 AsnAsnValLysSerValLeuLysSerAsnArgGlyIleThrAspVal 195200205 AspLeuArgLeuSerLysGlnAlaLysPheThrValAsnPheLysAsn 210215220 GlyThrLysLysValIleAspLeuLysAlaGlyIleTyrThrAlaAsn 225230235240 LeuIleAsnThrGlyGlyIleLysAsnIleAsnIleAsnValGluThr 245250255 LysLysGlnAlaLysAspLysGluAlaLysValAsnAsnGlnValPro 260265270 TyrSerIleAsnLeuAsnGlyThrThrThrAsnIleGlnSerAsnLeu 275280285 AlaPheSerAsnLysProTrpThrAsnTyrLysAsnLeuThrThrLys 290295300 ValLysSerValLeuLysSerAspArgGlyValSerGluArgAspLeu 305310315320 LysHisAlaLysLysAlaTyrTyrThrValTyrPheLysAsnGlyGly 325330335 LysArgValIleHisLeuAsnSerAsnIleTyrThrAlaAsnLeuVal 340345350 HisAlaLysAspValLysArgIleGluValThrValLysThrValSer 355360365 LysValLysAlaGluArgTyrValProTyrThrIleAlaValAsnGly 370375380 AlaSerAsnProThrLeuSerAspLeuLysPheThrGlyAspSerArg 385390395400 ValSerTyrSerAspIleLysLysLysValLysSerValLeuLysHis 405410415 AspArgGlyIleGlyGluArgGluLeuLysTyrAlaGluLysAlaThr 420425430 TyrThrValHisPheLysAsnGlyThrLysLysValIleAsnLeuAsn 435440445 SerAsnIleSerGlnLeuAsnLeuLeuTyrValLysAspIleLysAsn 450455460 IleAspIleAspValLysThrGlyAlaLysAlaLysValTyrSerTyr 465470475480 ValProTyrThrIleAlaValAsnGlyThrThrThrProIleAlaSer 485490495 LysLeuLysLeuSerAsnLysGlnLeuIleGlyTyrGlnAspLeuAsn 500505510 LysLysValLysSerValLeuLysHisAspArgGlyIleAsnAspIle 515520525 GluLeuLysPheAlaLysGlnAlaLysTyrThrIleHisPheLysAsn 530535540 GlyLysThrGlnValValAspLeuLysSerAspIlePheThrArgAsn 545550555560 LeuPheSerValLysAspIleLysLysIleAspIleAsnValLysGln 565570575 GlnSerLysSerAsnLysAlaLeuAsnLysValThrAsnLysAlaThr 580585590 LysValLysPheProValThrIleAsnGlyPheSerAsnLeuValSer 595600605 AsnGluPheAlaPheLeuHisProHisLysIleThrThrAsnAspLeu 610615620 AsnAlaLysLeuArgLeuAlaLeuArgSerAspGlnGlyIleThrLys 625630635640 HisAspIleGlyLeuSerGluArgThrValTyrLysValTyrPheLys 645650655 AspGlySerSerLysLeuGluAspLeuLysAlaAlaLysGlnAspSer 660665670 LysValPheLysAlaThrAspIleLysLysValAspIleGluIleLys 675680685 Phe (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AspIleAspLeuArgLeuSerLysGlnAlaLysTyrThrValHisPhe 151015 LysAsnGlyThrLysArgValValAspLeuLysAlaGlyIleHis 202530 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: AspValAspLeuArgLeuSerLysGlnAlaLysPheThrValAsnPhe 151015 LysAsnGlyThrLysLysValIleAspLeuLysAlaGlyIleTyr 202530 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GluArgAspLeuLysHisAlaLysLysAlaTyrTyrThrValTyrPhe 151015 LysAsnGlyGlyLysArgValIleHisLeuAsnSerAsnIleTyr 202530 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: GlyGluArgGluLeuLysTyrAlaGluLysAlaThrTyrThrValHis 151015 PheLysAsnGlyThrLysLysValIleAsnLeuAsnSerAsnIleSer 202530 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: AspIleGluLeuLysPheAlaLysGlnAlaLysTyrThrIleHisPhe 151015 LysAsnGlyLysThrGlnValValAspLeuLysSerAspIlePhe 202530 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: LysHisAspIleGlyLeuSerGluArgThrValTyrLysValTyrPhe 151015 LysAspGlySerSerLysLeuGluAspLeuLysAlaAlaLysGln 202530 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GlnGlnAspLysTyrGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgPheLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: GlnGlnAspLysTyrGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgPheLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GlnGlnAspLysTyrGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgPheLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: GlyAspThrGlnProArgPheLeuGluGlnAlaLysCysGluCysHis 151015 PheLeuAsnGlyThrGluArgValTrpAsnLeu 2025 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: AspThrGlnProArgPheLeuLysGlnAspLysPheGluCysHisPhe 151015 PheAsnGlyThrGluArgValArgTyrLeuHisArgGlyIleTyr 202530 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GlyAspThrGlnProArgPheLeuGluGlnAlaLysCysGluCysHis 151015 PheLeuAsnGlyThrGluArgValTrpAsnLeu 2025 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: ArgPheLeuLysGlnAspLysPheGluCysHisPhePheAsnGlyThr 151015 GluArgValArgTyrLeuHisArgGlyIleTyr 2025 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: LysGlnAspLysPheGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgTyrLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: LysGlnAspLysPheGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgTyrLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: LysGlnAspLysPheGluCysTyrPhePheAsnGlyThrGluArgVal 151015 ArgTyrLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AspThrArgProArgPheLeuGlnGlnAspLysTyrGluCysHisPhe 151015 PheAsnGlyThrGluArgValArgPheLeuHisArgGlyIleTyr 202530 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: AspThrArgProArgPheLeuGlnGlnAspLysTyrGluCysHisPhe 151015 PheAsnGlyThrGluArgValArgPheLeuHisArgAspIleTyr 202530 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: LysGlnGluLysTyrGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgPheLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: LysGlnAspLysTyrGluCysHisPhePheAsnGlyThrGluArgVal 151015 ArgTyrLeuHisArgGlyIleTyr 20 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: ArgPheLeuGluGlnAlaLysHisGluCysHisPheTyrAsnGlyThr 151015 GlnArgValArgPheLeuLeuArgGlnIleHis 2025 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: CGGGATCCGCAGCTAAGCAAATAGATA27 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GCGTCGACGCGGCAAATCACTTCAAGT27 __________________________________________________________________________

## Claims

1. A DNA segment comprising an isolated gene encoding a Staphylococcus aureus broad spectrum adhesin that has a molecular weight of about 70 kDa as determined by SDS gel electrophoresis, said adhesin capable of binding fibronectin or vitronectin wherein said adhesin comprises a MHC II mimicking unit of about 30 amino acids.

2. The DNA of SEQ ID NO:1 or fragment thereof that encodes a protein or peptide that is capable of binding fibronectin or vitronectin or that comprises a MHC II mimicking unit of about 30 amino acids.

3. The DNA of claim 2 that encodes a protein or peptide that encompasses a MHC II mimicking unit.

4. The DNA of claim 2 that encodes a protein or peptide that binds to fibronectin or vitronectin.

5. The DNA of claim 2, comprising a gene that encodes a protein of about 689 amino acids in length.

6. The DNA of claim 2, positioned under the control of a promoter.

7. A recombinant vector comprising the DNA segment of claim 2.

8. The vector of claim 7, further defined as pQE20.

9. A recombinant host cell transformed with the vector of claim 7.

10. The recombinant host cell of claim 9, further defined as a bacterial host cell.

11. The recombinant host cell of claim 10, wherein the bacterial host cell is E. coli.

12. The recombinant host cell of claim 9, that expresses the polypeptide encoded by the DNA of claim 2.

13. A fragment of the DNA sequence of SEQ ID NO:1 that hybridizes to the DNA sequence of claim 2.

14. The DNA of claim 13, wherein the segment is SEQ ID NO:1.

15. The DNA of claim 13, that is the complement of SEQ ID NO:1.

16. The DNA of claim 13, wherein the segment comprises residues 71 to 2134 of FIG. 2.

17. The DNA of claim 13, which encodes an amino acid sequence set forth by any one of SEQ ID NOS:2, 3, 4, 5, 6, 7, or 8.

18. An isolated nucleic acid composition comprising the DNA sequence of SEQ ID NO:1 or the complement thereof in a suitable buffer.

19. A composition comprising a protein or polypeptide encoded by the DNA of claim 2 and a pharmaceutically acceptable excipient.

20. The composition of claim 19, comprising a peptide that consists of the amino sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

21. A method of inducing an immune response in an animal comprising administering to an animal an immunogenic composition comprising the composition of claim 19 and a pharmaceutically acceptable dispensing agent.

22. A method of making a MHC II-antigen protein analog comprising the steps of inserting the DNA of SEQ ID NO:1 in a suitable expression vector and culturing a host cell transformed with said vector under conditions to produce said MHC II-antigen protein analog.

23. A method of inducing an immune response to Staphylococcus aureus comprising the steps of administering to an individual suspected of being susceptible to or having a staphylococcal infection a pharmaceutically acceptable composition in accordance with claim 19.